Compare Moderna, Inc. (MRNA) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PPG Industries, Inc. — how do they compare? Moderna, Inc. trades at $63.65 (market cap $24.18B), while PPG Industries, Inc. trades at $115.82 (market cap $25.82B). The key difference: Moderna, Inc. and PPG Industries, Inc. are close in size by market cap, and PPG Industries, Inc. pays a 2.55% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PPG | |
|---|---|---|
Market Cap | $24.18B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $81.80 | $131.56 |
52-Week Low | $22.36 | $94.34 |
Enterprise Value | $20.33B | $31.69B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
PPG Industries trades at $114.61, down 0.74% on the day, with mixed technical signals showing a neutral overall outlook. The company reported Q2 2026 earnings of $2.23 per share, slightly missing estimates despite 7% revenue growth. Fundamentals remain solid with a 9.57% net margin and 19.63% ROE, while valuation metrics appear reasonable with a P/E of 16.67. Recent developments include a dividend increase to $0.74 per share and leadership changes in Industrial Coatings.
PPG presents a balanced investment case with strong profitability and shareholder returns offset by recent earnings misses. The 12% upside to consensus price target of $129.17 suggests moderate growth potential, though investors face risks from raw material cost pressures and competitive market conditions. The company's consistent dividend history and improving cash flow support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
